OZOBAX Drug Patent Profile
✉ Email this page to a colleague
When do Ozobax patents expire, and what generic alternatives are available?
Ozobax is a drug marketed by Metacel Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
The generic ingredient in OZOBAX is baclofen. There are twenty-one drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ozobax
A generic version of OZOBAX was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.
Summary for OZOBAX
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 145 |
| Patent Applications: | 3,919 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in OZOBAX? | OZOBAX excipients list |
| DailyMed Link: | OZOBAX at DailyMed |
Pharmacology for OZOBAX
| Drug Class | gamma-Aminobutyric Acid-ergic Agonist |
| Mechanism of Action | GABA A Agonists GABA B Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for OZOBAX
US Patents and Regulatory Information for OZOBAX
OZOBAX is protected by one US patents.
Patents protecting OZOBAX
Oral baclofen solutions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SPASTICITY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metacel Pharms Llc | OZOBAX | baclofen | SOLUTION;ORAL | 208193-001 | Sep 18, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
